October 8, 2010

Integra LifeSciences Features the Inforce(R) Reinforcement Matrix at the 65th Annual ASSH Meeting

PLAINSBORO, N.J., Oct. 8, 2010 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it is featuring the Inforce® Reinforcement Matrix at the 65th Annual Meeting of the American Society for Surgery of the Hand (ASSH) on October 7-9, in Boston, Massachusetts. 

The Inforce® Reinforcement Matrix, with FortaFlexTM Technology, is a biological implant with high bio-mechanical strength that may be used for any type of tendon injury that requires surgical reconstruction, and provides a durable reinforcement during the healing phase of a repaired tendon. The Inforce® matrix is composed of a biocompatible, purified collagen matrix, designed to provide an organized scaffold that facilitates cellular attachment and integration of the implant at a controlled rate of in situ remodeling. The matrix is purified to remove non-collagenous materials that may cause inflammatory or immunological responses. The Inforce® matrix is a ready-to-use product, delivered hydrated and requiring no special handling or storage, and may be trimmed to the desired size to accommodate a wide variety of procedures.

"Inforce® Reinforcement Matrix is an excellent complement to our family of tendon protection products that includes our innovative TenoGlide® Tendon Protector Sheet technology, and offers our upper extremity surgeon customers' additional choices for patient treatment," said Robert Paltridge, President of Integra Extremity Reconstruction.

Tendon and ligament injuries are some of the most common musculoskeletal disorders, ranging from an Achilles tendon rupture to a flexor tendon injury of the hand. Industry sources estimate that there are approximately 700,000 tendon and ligament repair procedures in the U.S., representing a $1.2 billion market.

The Inforce® Reinforcement Matrix is sold by Integra's Extremity Reconstruction sales organization, which focuses on lower extremity reconstruction, upper extremity reconstruction, tendon protection/augmentation, peripheral nerve repair/protection, and wound repair.

Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care.  Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com

FortaFlex is a trademark of Organogenesis, Inc.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products.  Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results.  Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures.  In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-P

CONTACT:  Integra LifeSciences Holdings Corporation
          Gianna Sabella, Director, Corporate Communications
          (609) 936-2389
          gianna.sabella@integralife.com

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.


Close window | Back to top

Copyright 2014 Integra LifeSciences Holdings Corporation